Brian Finan, head of obesity research at Novo Nordisk, said the company is "excited about the opportunity to advance Embark Biotech's lead programme" and looks forward to "co-creating novel ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year ...

LONDON — An experimental weight loss drug from Novo Nordisk helped patients shed a ... Novo as companies race to develop next-generation obesity treatments. Shares of Novo were up more than ...